ATE319105T1 - Nmr-verfahren zur bestimmung des risikos zur entwicklung von diabetes type 2 - Google Patents
Nmr-verfahren zur bestimmung des risikos zur entwicklung von diabetes type 2Info
- Publication number
- ATE319105T1 ATE319105T1 AT00926111T AT00926111T ATE319105T1 AT E319105 T1 ATE319105 T1 AT E319105T1 AT 00926111 T AT00926111 T AT 00926111T AT 00926111 T AT00926111 T AT 00926111T AT E319105 T1 ATE319105 T1 AT E319105T1
- Authority
- AT
- Austria
- Prior art keywords
- nmr
- diabetes
- patient
- glucose concentration
- lipoprotein
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title abstract 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 4
- 239000008103 glucose Substances 0.000 abstract 4
- 239000000523 sample Substances 0.000 abstract 4
- 238000012360 testing method Methods 0.000 abstract 4
- 108090001030 Lipoproteins Proteins 0.000 abstract 3
- 102000004895 Lipoproteins Human genes 0.000 abstract 3
- 239000008280 blood Substances 0.000 abstract 3
- 210000004369 blood Anatomy 0.000 abstract 3
- 239000000470 constituent Substances 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 238000011156 evaluation Methods 0.000 abstract 2
- 238000012216 screening Methods 0.000 abstract 2
- 238000001228 spectrum Methods 0.000 abstract 2
- 206010070901 Diabetic dyslipidaemia Diseases 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 abstract 1
- 239000013610 patient sample Substances 0.000 abstract 1
- 238000012502 risk assessment Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/46—NMR spectroscopy
- G01R33/465—NMR spectroscopy applied to biological material, e.g. in vitro testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
- G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
- Y10T436/144444—Glucose
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Spectroscopy & Molecular Physics (AREA)
- High Energy & Nuclear Physics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13061299P | 1999-04-22 | 1999-04-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE319105T1 true ATE319105T1 (de) | 2006-03-15 |
Family
ID=22445506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00926111T ATE319105T1 (de) | 1999-04-22 | 2000-04-19 | Nmr-verfahren zur bestimmung des risikos zur entwicklung von diabetes type 2 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6518069B1 (de) |
| EP (1) | EP1171778B1 (de) |
| JP (1) | JP4585693B2 (de) |
| AT (1) | ATE319105T1 (de) |
| AU (1) | AU4469300A (de) |
| CA (1) | CA2367820C (de) |
| DE (1) | DE60026287T2 (de) |
| ES (1) | ES2256000T3 (de) |
| WO (1) | WO2000065366A1 (de) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7395158B2 (en) * | 2000-05-30 | 2008-07-01 | Sensys Medical, Inc. | Method of screening for disorders of glucose metabolism |
| US20040236673A1 (en) * | 2000-10-17 | 2004-11-25 | Eder Jeff Scott | Collaborative risk transfer system |
| CA2331116A1 (en) | 2001-01-15 | 2002-07-15 | Chenomx, Inc. | Compound identification and quantitation in liquid mixtures -- method and process using an automated nuclear magnetic resonance measurement system |
| US7043288B2 (en) | 2002-04-04 | 2006-05-09 | Inlight Solutions, Inc. | Apparatus and method for spectroscopic analysis of tissue to detect diabetes in an individual |
| US20040214348A1 (en) * | 2001-04-23 | 2004-10-28 | Nicholson Jeremy Kirk | Methods for analysis of spectral data and their applications: osteoarthritis |
| US7901873B2 (en) | 2001-04-23 | 2011-03-08 | Tcp Innovations Limited | Methods for the diagnosis and treatment of bone disorders |
| US20040142403A1 (en) * | 2001-08-13 | 2004-07-22 | Donald Hetzel | Method of screening for disorders of glucose metabolism |
| ATE525635T1 (de) | 2001-11-13 | 2011-10-15 | Univ California | Ionenmobilitätsanalyse biologischer partikel |
| US20040019430A1 (en) | 2001-11-21 | 2004-01-29 | Patrick Hurban | Methods and systems for analyzing complex biological systems |
| US6862592B1 (en) * | 2001-12-21 | 2005-03-01 | Adobe Systems Incorporated | Document processing in a cross-platform environment |
| EP1329716A1 (de) * | 2002-01-16 | 2003-07-23 | Roche Diagnostics GmbH | Verfahren zum Austesten biologischer Proben auf Vorliegen von Stoffwechselsyndrom |
| US20070011049A1 (en) * | 2005-07-09 | 2007-01-11 | Eder Jeffrey S | Intelligent, personalized commerce chain |
| US7730063B2 (en) * | 2002-12-10 | 2010-06-01 | Asset Trust, Inc. | Personalized medicine service |
| US20080027769A1 (en) * | 2002-09-09 | 2008-01-31 | Jeff Scott Eder | Knowledge based performance management system |
| US7426499B2 (en) * | 2004-11-08 | 2008-09-16 | Asset Trust, Inc. | Search ranking system |
| US7243030B2 (en) * | 2002-10-25 | 2007-07-10 | Liposcience, Inc. | Methods, systems and computer programs for deconvolving the spectral contribution of chemical constituents with overlapping signals |
| DE10315877B4 (de) * | 2003-04-08 | 2005-11-17 | Roche Diagnostics Gmbh | Krankheitsverlaufkontrolle |
| US8460243B2 (en) * | 2003-06-10 | 2013-06-11 | Abbott Diabetes Care Inc. | Glucose measuring module and insulin pump combination |
| US7722536B2 (en) | 2003-07-15 | 2010-05-25 | Abbott Diabetes Care Inc. | Glucose measuring device integrated into a holster for a personal area network device |
| US7197427B2 (en) * | 2004-03-31 | 2007-03-27 | Genworth Financial Inc. | Method for risk based testing |
| EP1735631A2 (de) * | 2004-04-01 | 2006-12-27 | Liposcience, Inc. | Klinische nmr-analysierer und diesbezügliche verfahren, systeme, module und computerprogrammprodukte zur klinischen auswertung von bioproben |
| US7422224B2 (en) * | 2004-04-13 | 2008-09-09 | Kimir Seatpost | Adjustable bicycle seat post assembly |
| CA3110101A1 (en) | 2004-06-04 | 2005-12-15 | Abbott Diabetes Care Inc. | Systems and methods for managing diabetes care data |
| US7951078B2 (en) * | 2005-02-03 | 2011-05-31 | Maren Theresa Scheuner | Method and apparatus for determining familial risk of disease |
| EP1702559B1 (de) | 2005-03-15 | 2008-10-29 | Roche Diagnostics GmbH | Verfahren und System zur Untersuchung des Glucosestoffwechsels |
| WO2007110357A2 (en) * | 2006-03-24 | 2007-10-04 | Metanomics Gmbh | Means and method for diagnosing diabetes |
| US8498915B2 (en) * | 2006-04-02 | 2013-07-30 | Asset Reliance, Inc. | Data processing framework for financial services |
| US8247235B2 (en) | 2007-06-08 | 2012-08-21 | Quest Diagnostics Investments Incorporated | Lipoprotein analysis by differential charged-particle mobility |
| US8420088B2 (en) | 2008-01-28 | 2013-04-16 | Novartis Ag | Methods and compositions using FGF23 fusion polypeptides |
| TW200936156A (en) | 2008-01-28 | 2009-09-01 | Novartis Ag | Methods and compositions using Klotho-FGF fusion polypeptides |
| US9354200B1 (en) | 2008-08-07 | 2016-05-31 | Quest Diagnostics Investments Incorporated | Detection apparatus for differential-charged particle mobility analyzer |
| WO2010047767A2 (en) | 2008-10-20 | 2010-04-29 | Liposcience, Inc. | Lipoprotein insulin resistance indexes and related methods, systems and computer programs for generating same |
| DE102009026651A1 (de) | 2009-06-02 | 2011-02-17 | Großmann, Kay, Dr. rer. nat. (Chemie) | Verfahren und Messvorrichtung zur qualitativen und quantitativen Analyse von Körperflüssigkeiten |
| US9250211B2 (en) | 2010-12-30 | 2016-02-02 | Quest Diagnostics Investments Incorporated | Magnetic separation of lipoproteins using dextran sulfate |
| US10136845B2 (en) | 2011-02-28 | 2018-11-27 | Abbott Diabetes Care Inc. | Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same |
| WO2012163361A1 (en) * | 2011-05-31 | 2012-12-06 | Aarhus Universitet | Method and system for identification of physiological imbalance in an animal |
| SG10201608139VA (en) | 2011-06-30 | 2016-11-29 | Liposcience Inc | Quantitative nmr clinical analyzers with automatic nmr temperature sensitivity compensation that accommodate large ambient operational temperature ranges |
| WO2013027191A1 (en) | 2011-08-25 | 2013-02-28 | Novartis Ag | Methods and compositions using fgf23 fusion polypeptides |
| US9470771B2 (en) | 2012-06-08 | 2016-10-18 | Liposcience, Inc. | NMR measurements of NMR biomarker GlycA |
| US9928345B2 (en) | 2012-06-08 | 2018-03-27 | Liposciences, Inc. | Multiple-marker risk parameters predictive of conversion to diabetes |
| US9361429B2 (en) | 2012-06-08 | 2016-06-07 | Liposcience, Inc. | Multi-parameter diabetes risk evaluations |
| US9551768B2 (en) | 2013-03-15 | 2017-01-24 | East Carolina University | NMR method for monitoring changes in the core of lipoprotein particles in metabolism and disease |
| US20150260631A1 (en) * | 2014-03-17 | 2015-09-17 | Health Diagnostic Laboratory, Inc. | System and method for assessing quanitites or sizes of lipoprotein particles from lipoprotein particle compositions |
| DE102014203721B4 (de) * | 2014-02-28 | 2018-12-27 | Bruker Biospin Gmbh | Verfahren zur Bestimmung der Konzentration einer Substanz in einer Probe |
| US20160109471A1 (en) | 2014-10-21 | 2016-04-21 | Health Diagnostic Laboratory, Inc. | Lipoprotein particle number from measurements of lipoprotein particle phospholipid concentration in lipoprotein particle membrane bilayer |
| CA2965172A1 (en) | 2014-10-21 | 2016-04-28 | Philip Guadagno | Quantitative molar concentration detection of specific apolipoprotein-containing particles present in bodily fluids by using capillary electrophoresis |
| WO2016069639A1 (en) | 2014-10-27 | 2016-05-06 | True Health Diagnostics, Llc | Lp(a) subform size identification by capillary isoteachophoresis electrophoresis with laser-induced-fluorescence |
| EP3227319B1 (de) | 2014-12-04 | 2019-11-27 | Novartis AG | Verfahren und zusammensetzungen mit polypeptiden der klotho-variante |
| WO2019051226A1 (en) * | 2017-09-07 | 2019-03-14 | Liposcience, Inc. | METABOLIC VULNERABILITY INDEX ASSESSMENTS WITH MULTIPLE PARAMETERS |
| US10775458B2 (en) | 2018-03-05 | 2020-09-15 | Texas Tech University System | Method and system for non-invasive measurement of metabolic health |
| EP4537110A1 (de) * | 2022-06-09 | 2025-04-16 | Quest Diagnostics Investments LLC | Quantifizierung von lipoprotein-subfraktionen durch ionenmobilität |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5869534A (en) * | 1992-05-21 | 1999-02-09 | The Picower Institute For Medical Research | Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom |
| US4933844A (en) | 1988-09-26 | 1990-06-12 | Otvos James D | Measurement of blood lipoprotein constituents by analysis of data acquired from an NMR spectrometer |
| WO1991010128A1 (en) | 1989-12-21 | 1991-07-11 | The Beth Israel Hospital Association | Method for predicting atherosclerotic risk |
| WO1993003450A1 (en) | 1991-07-30 | 1993-02-18 | North Carolina State University | Method and apparatus for measuring blood lipoprotein levels by nmr spectroscopy |
| US5585235A (en) * | 1993-04-13 | 1996-12-17 | Diagnescent Technologies, Inc. | Fluorescent assay and method that corrects for spectral interference |
| WO1995013096A1 (en) * | 1993-11-08 | 1995-05-18 | Peptide Delivery Systems Pty. Ltd. | Labelled diagnostic compositions and methods of their use |
| US5685300A (en) * | 1994-04-01 | 1997-11-11 | Kuenstner; J. Todd | Noninvasive and in-vitro measurement of glucose and cholesterol by nuclear magnetic resonance spectroscopy |
| US6163154A (en) | 1997-12-23 | 2000-12-19 | Magnetic Diagnostics, Inc. | Small scale NMR spectroscopic apparatus and method |
| US6226082B1 (en) | 1998-06-25 | 2001-05-01 | Amira Medical | Method and apparatus for the quantitative analysis of a liquid sample with surface enhanced spectroscopy |
-
2000
- 2000-04-19 ES ES00926111T patent/ES2256000T3/es not_active Expired - Lifetime
- 2000-04-19 US US09/550,359 patent/US6518069B1/en not_active Expired - Lifetime
- 2000-04-19 CA CA002367820A patent/CA2367820C/en not_active Expired - Fee Related
- 2000-04-19 DE DE60026287T patent/DE60026287T2/de not_active Expired - Lifetime
- 2000-04-19 AU AU44693/00A patent/AU4469300A/en not_active Abandoned
- 2000-04-19 EP EP00926111A patent/EP1171778B1/de not_active Expired - Lifetime
- 2000-04-19 AT AT00926111T patent/ATE319105T1/de not_active IP Right Cessation
- 2000-04-19 JP JP2000614054A patent/JP4585693B2/ja not_active Expired - Fee Related
- 2000-04-19 WO PCT/US2000/010463 patent/WO2000065366A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP4585693B2 (ja) | 2010-11-24 |
| AU4469300A (en) | 2000-11-10 |
| CA2367820A1 (en) | 2000-11-02 |
| DE60026287D1 (de) | 2006-04-27 |
| EP1171778B1 (de) | 2006-03-01 |
| JP2002543392A (ja) | 2002-12-17 |
| WO2000065366A8 (en) | 2001-03-29 |
| DE60026287T2 (de) | 2006-08-17 |
| CA2367820C (en) | 2009-12-22 |
| EP1171778A1 (de) | 2002-01-16 |
| US6518069B1 (en) | 2003-02-11 |
| WO2000065366A1 (en) | 2000-11-02 |
| ES2256000T3 (es) | 2006-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60026287D1 (de) | Nmr-verfahren zur bestimmung des risikos zur entwicklung von diabetes type 2 | |
| Nederveen et al. | Variability in skeletal muscle fibre characteristics during repeated muscle biopsy sampling in human vastus lateralis | |
| Cao et al. | Validation of capillary blood analysis and capillary testing mode on the epoc Point of Care system | |
| Price | Point-of-care testing in diabetes mellitus. | |
| Dubayová et al. | Diagnostic monitoring of urine by means of synchronous fluorescence spectrum | |
| CN111063440A (zh) | 早期非酒精性脂肪性肝病评估模型、构建方法及其应用 | |
| CN109781701A (zh) | 一种基于拉曼光谱技术的甲状旁腺术中实时检测方法 | |
| Wikblad et al. | Outcome of clinical foot examination in relation to self-perceived health and glycaemic control in a group of urban Tanzanian diabetic patients | |
| Miyamoto | Clinical application of plasma clearance of iohexol on feline patients | |
| US20080269616A1 (en) | Mir spectroscopy of tissue | |
| US6424859B2 (en) | Diagnosis of rheumatoid arthritis in vivo using a novel spectroscopic approach | |
| CA3016500C (en) | Direct infrared analysis of post-translational modification of proteins | |
| Yang et al. | Monitoring rotator cuff muscle fatty infiltration progression by magnetic resonance imaging T1 mapping: correlation with direct evaluation findings in rats | |
| Schulman et al. | Use of the Accusport semi-automated analyser to determine blood lactate as an aid in the clinical assessment of horses with colic | |
| Meites et al. | Studies on the quality of specimens obtained by skin puncture of children 1. Tendency to hemolysis, and hemoglobin and tissue fluid as contaminants. | |
| Ross et al. | Short-term evaluation of an electro-chemical system (ExacTech™) for blood glucose monitoring | |
| Holstein et al. | Practicality and accuracy of prehospital rapid venous blood glucose determination | |
| Peyron et al. | Usefulness of a blood glucose and ketone monitoring device as a screening tool for lethal diabetic ketoacidosis | |
| Bock et al. | Evaluation of CK-MB isoform analysis for early diagnosis of myocardial infarction | |
| Krøll et al. | On the use of patient data for the definition of reference intervals in clinical chemistry | |
| Young et al. | Performance evaluation of a new blood glucose monitor that requires no coding: the OneTouch® Vita™ system | |
| Joy et al. | Glycemic control and clinico-electrophysiological severity of diabetic polyneuropathy | |
| Uluc et al. | Near‐nerve needle sensory and medial plantar nerve conduction studies in patients with small‐fiber sensory neuropathy | |
| Pardue et al. | Unifying approach to analytical chemistry and chemical analysis, problem-oriented role of chemical analysis | |
| Wong et al. | ‘Office-hour’ambulatory blood pressure monitoring is sufficient for blood pressure diagnosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |